Anchor Therapeutics is categorized under Medical Research in Cambridge, MA and active since 2006.
Anchor Therapeutics was established in 2006, and today employs 1 to 4, earning Unknown per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 5417114 by the NAICS.
If you are seeking more information, feel free to contact Frederick Jones, Chief Executive Officer at the company’s single location by writing to 1 Kendall Square # B6101, Cambridge, Massachusetts MA 02139 or by phoning (617) 715-1999. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Anchor Therapeutics |
| Contact Person: | Frederick Jones, Chief Executive Officer |
| Address: | 1 Kendall Square # B6101, Cambridge, Massachusetts 02139 |
| Phone Number: | (617) 715-1999 |
| Website Address: | anchortx.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 2006 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Medical Research |
| SIC Code: | 8733 |
| NAICS Code: | 5417114 |
| Share This Business: |
Anchor Therapeutics was started in 2006 to provide professional Medical Research under the SIC code 8733 and NAICS code 5417114. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Frederick Jones, Chief Executive Officer for inquiries that concern Anchor Therapeutics by calling the company number (617) 715-1999, as your correspondence is most welcome. Additionally, the physical location of the single location of Anchor Therapeutics can be found at the coordinates 42.3631,-71.1033 as well as the street address 1 Kendall Square # B6101 in Cambridge, Massachusetts 02139.
For its online presence, you may visit Anchor Therapeutics’s website at anchortx.com and engage with its social media outlets through on Twitter and on Facebook.